This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Comparison of Patients and Controls

K. Peter Lesch, MD; Angelika Hoh, MD; Jörg Disselkamp-Tietze, MD; Martin Wiesmann, MD; Michael Osterheider, MD; Heinrich M. Schulte, MD

Arch Gen Psychiatry. 1991;48(6):540-547.

Abstract
• To evaluate 5-hydroxytryptamine_1A receptor responsivity in obsessive-compulsive disorder, we examined hypothermic, neuroendocrine, and behavioral responses to the selective 5-hydroxytryptamine_1A receptor ligand ipsapirone in patients with primary obsessive-compulsive disorder and healthy controls. Twelve patients and 22 controls received a single dose of ipsapirone, 0.3 mg/kg, or placebo under double-blind, random assignment conditions. Ipsapirone induced hypothermia and release of corticotropin and cortisol but had no effect on behavior, including obsessive or compulsive symptoms. Thermoregulatory and neuroendocrine responses to ipsapirone were not consistently different between healthy controls and patients with obsessive-compulsive disorder. These results provide no direct support for the hypothesis that a serotonergic dysfunction related to 5-hydroxytryptamine_1A receptors may be linked to the pathophysiologic characteristics of obsessive-compulsive disorder and point to the need for the evaluation of other 5-hydroxytryptamine receptor subtypes. Future studies of the responsivity of 5-hydroxytryptamine_1A receptors to direct-acting ligands, such as ipsapirone, should facilitate assessment of the integrity of the 5-hydroxytryptamine system and its involvement in antiobsessional drug effects.

Author Affiliations
From the Department of Psychiatry, University of Würzburg (Drs Lesch, Hoh, Disselkamp-Tietze, Wiesmann, and Osterheider), and the Department of Medicine I, University of Kiel (Dr Schulte), Germany.

Footnotes
Accepted for publication September 26, 1990.

Presented in part at the Eighth World Congress of Psychiatry, Athens, Greece, October 18, 1989.

Reprint requests to Laboratory of Clinical Science, NIMH, NIH Clinical Center, 10/3D41, 9000 Rockville Pike, Bethesda, MD 20892 (Dr Lesch).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

5-Hydroxytryptamine 1A Receptors in the Paraventricular Nucleus of the Hypothalamus Mediate Oxytocin and Adrenocorticotropin Hormone Release and Some Behavioral Components of the Serotonin Syndrome
Osei-Owusu et al.
J. Pharmacol. Exp. Ther. 2005;313:1324-1330.
ABSTRACT | FULL TEXT  

S 15535, A Novel Benzodioxopiperazine Ligand of Serotonin (5-HT)1A Receptors: II. Modulation of Hippocampal Serotonin Release in Relation to Potential Anxiolytic Properties
Millan et al.
J. Pharmacol. Exp. Ther. 1997;282:148-161.
ABSTRACT | FULL TEXT  

BAP/SKB Young Psychopharmacologist Award Towards a neuroendocrinology of obsessive-compulsive disorder
Lucey
J Psychopharmacol 1994;8:250-257.
ABSTRACT  

Psychiatry
Freedman and Stahl
JAMA 1992;268:403-405.
ABSTRACT